Results from a first-in-human phase I study of F182112, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma.

被引：0
|
作者：
Sun, Mingyuan
Qiu, Lugui
Wei, Yongqiang
Jin, Jie
Li, Xin
Liu, Xue
Yin, Shaohong
Qi, Junyuan
机构：
[1] Natl Clin Res Ctr Hematol Disorders, Inst Hematol & Blood Dis Hosp, State Key Lab Expt Hematol, Tianjin, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Co, Inst Hematol, State Key Lab Expt Hematol, Tianjin, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Co, Blood Dis Hosp, Tianjin, Peoples R China
[4] Southern Med Univ, Nanfang Hosp, Guangzhou, Peoples R China
[5] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Hangzhou, Zhejiang, Peoples R China
[6] Cent South Univ, Xiangya Hosp 3, Dept Hematol, Changsha, Peoples R China
[7] Lunan Pharmaceut Grp Co LTD, Linyi, Shandong, Peoples R China
[8] Chinese Acad Med Sci, Blood Inst, Tianjin, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8038
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma
    Plesner T.
    Harrison S.J.
    Quach H.
    Lee C.
    Bryant A.
    Vangsted A.
    Estell J.
    Delforge M.
    Offner F.
    Twomey P.
    Choeurng V.
    Li J.
    Hendricks R.
    Ruppert S.M.
    Sumiyoshi T.
    Miller K.
    Cho E.
    Schjesvold F.
    Clinical Hematology International, 2023, 5 (1) : 43 - 51
  • [42] Expression of Myeloma Cell and Soluble B-Cell Maturation Antigen (BCMA) in Relapsed and Refractory Multiple Myeloma Patients Treated with GSK2857916 in BMA117159
    Dettman, E. J.
    Rigat, Fabio
    Albert, Josh
    Barnard, Ruth
    Birchler, Mary
    Deghenhardt, Yan
    DeWall, Stephen
    Gaye, Boyenoh
    He, Zangdong
    Liu, Veronica
    Opalinska, Joanna
    BLOOD, 2018, 132
  • [43] Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Multiple Myeloma
    Kumar, Shaji K.
    Migkou, Magdalini
    Bhutani, Manisha
    Spencer, Andrew
    Ailawadhi, Sikander
    Kalff, Anna
    Walcott, Farzana
    Pore, Nabendu
    Gibson, Diana
    Wang, Fujun
    Cheng, Lily
    Kagiampakis, Ioannis
    Williams, Marna
    Kinneer, Krista
    Jiang, Yu
    Zonder, Jeffrey
    Larsen, Jeremy
    Sirdesai, Shreerang
    Yee, Andrew J.
    Dimopoulos, Meletios A.
    BLOOD, 2020, 136
  • [44] Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma
    Dimopoulos, Meletios A.
    Migkou, Magdalini
    Bhutani, Manisha
    Ailawadhi, Sikander
    Kalff, Anna
    Walcott, Farzana L.
    Pore, Nabendu
    Brown, Miranda
    Wang, Fujun
    Cheng, Lily I.
    Kagiampakis, Ioannis
    Williams, Marna
    Kinneer, Krista
    Wu, Yuling
    Jiang, Yu
    Kubiak, Robert J.
    Zonder, Jeffrey A.
    Larsen, Jeremy
    Sirdesai, Shreerang
    Yee, Andrew J.
    Kumar, Shaji
    LEUKEMIA & LYMPHOMA, 2024, 65 (12) : 1789 - 1800
  • [45] A novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma (RRMM): Updated phase 1b results for daratumumab in combination with teclistamab (a BCMA x CD3 bispecific antibody).
    Rodriguez-Otero, Paula
    D'Souza, Anita
    Reece, Donna Ellen
    van de Donk, Niels W. C. J.
    Chari, Ajai
    Krishnan, Amrita Y.
    Martin, Thomas G.
    Mateos, Maria-Victoria
    Morillo, Daniel
    Hurd, David Duane
    Rosinol, Laura
    Balari, Anna Sureda
    Wasch, Ralph
    Vishwamitra, Deeksha
    Lin, Shun Xin Wang
    Prior, Thomas
    Vandenberk, Lien
    Smit, Marie-Anne Damiette
    Rocafiguera, Albert Oriol
    Dholaria, Bhagirathbhai R.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.
    Berdeja, Jesus G.
    Madduri, Deepu
    Usmani, Saad Zafar
    Singh, Indrajeet
    Zudaire, Enrique
    Yeh, Tzu-Min
    Allred, Alicia J.
    Olyslager, Yunsi
    Banerjee, Arnob
    Goldberg, Jenna D.
    Schecter, Jordan
    Geng, Dong
    Wu, Xiaoling
    Carrasco-Alfonso, Marlene
    Rizvi, Syed
    Fan, Frank
    Jakubowiak, Andrzej J.
    Jagannath, Sundar
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [47] Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA x CD3 T-cell engager, in patients (pts) with relapsed/refractory multiple myeloma (RRMM): latest results from a phase 1 first-in-human clinical study
    Costa, Luciano
    Bar, Noffar
    Mateos, Maria-Victoria
    Ribas, Paz
    Hansson, Markus
    Paris, Laura
    Hofmeister, Craig
    Rodriguez-Otero, Paula
    Bermudez, Maria Aranzazu
    Santoro, Armando
    Yee, Andrew
    Creignou, Maria
    Encinas, Cristina
    Cerchione, Claudio
    de la Rubia, Javier
    Oriol, Albert
    Ferstl, Barbara
    Besemer, Britta
    Chen, Jinjie
    Boss, Isaac
    Gaudy, Allison
    Hsu, Kevin
    Godwin, Colin
    San-Miguel, Jesus
    Wong, Sandy
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S52 - S53
  • [48] Treatment with AMG 420, an Anti-B-Cell Maturation Antigen (BCMA) Bispecific T-Cell Engager (BiTE®) Antibody Construct, Induces Minimal Residual Disease (MRD) Negative Complete Responses in Relapsed and/or Refractory (R/R) Multiple Myeloma (MM) Patients: Results of a First-in-Human (FIH) Phase I Dose Escalation Study
    Topp, Max S.
    Duell, Johannes
    Zugmaier, Gerhard
    Attal, Michel
    Moreau, Philippe
    Langer, Christian
    Kroenke, Jan
    Facon, Thierry
    Einsele, Hermann
    Munzert, Gerd
    BLOOD, 2018, 132
  • [49] Updated Phase 1 Results from MonumenTAL-1: First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
    Krishnan, Amrita Y.
    Minnema, Monique C.
    Berdeja, Jesus G.
    Oriol, Albert
    van de Donk, Niels W. C. J.
    Rodriguez-Otero, Paula
    Askari, Elham
    Mateos, Maria-Victoria
    Costa, Luciano J.
    Verona, Raluca I.
    Ma, Xuewen
    Girgis, Suzette
    Yang, Shiyi
    Hilder, Brandi W.
    Russell, Jeffery
    Goldberg, Jenna D.
    Chari, Ajai
    BLOOD, 2021, 138
  • [50] Outcomes of Patients Who Are BCMA (B-cell maturation Antigen) Directed Therapy (BDT) Exposed Vs BCMA Naive in Penta-Relapsed Refractory Multiple Myeloma (RRMM)
    Mammadzadeh, Aytaj
    Peng, Fulei
    Atrash, Shebli
    Hashmi, Hamza
    Mohan, Meera
    Alkharabsheh, Omar
    Afrough, Aimaz
    Cui, Wei
    Mahmoudjafari, Zahra
    Abdallah, Al-Ola
    BLOOD, 2022, 140 : 4277 - 4278
12345